FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trialResearch in context
Summary: Background: Currently, assessment of candidate pharmacotherapies in patients with non-alcoholic steatohepatitis (NASH) involves invasive liver biopsy. Non-invasive scores, such as the FibroScan-aspartate aminotransferase (FAST) score, are used to identify candidates for therapy, but their...
Hlavní autoři: | , , , , , , , , , |
---|---|
Médium: | Článek |
Jazyk: | English |
Vydáno: |
Elsevier
2023-12-01
|
Edice: | EClinicalMedicine |
Témata: | |
On-line přístup: | http://www.sciencedirect.com/science/article/pii/S258953702300487X |